What's Happening?
A phase 3 trial has shown that the drug daraxonrasib nearly doubles the median overall survival for patients with previously treated metastatic pancreatic cancer. The trial involved 500 patients and extended survival to 13.2 months compared to 6.7 months with standard
chemotherapy. Despite not being a cure, the drug represents a significant advancement in treating a cancer with a high mortality rate. Daraxonrasib targets the KRAS gene, which is mutated in over 90% of pancreatic tumors. The drug is not yet approved, but an expanded access protocol allows certain patients to receive it outside of clinical trials.
Why It's Important?
This development is crucial as pancreatic cancer is one of the deadliest cancers, with a very low five-year survival rate. The drug's ability to extend survival offers hope for patients with limited treatment options. The trial's success highlights the potential of targeting the KRAS gene, previously considered undruggable, and could lead to new treatment paradigms. The expanded access protocol provides a pathway for patients to access the drug, potentially improving outcomes for those who cannot participate in clinical trials.
What's Next?
Further trials are underway to evaluate daraxonrasib in different settings, including as a first-line treatment and post-surgery. The FDA has not yet approved the drug, but it holds Breakthrough Therapy designation, which could expedite its review. Patients and families are advised to confirm molecular testing for RAS mutations and inquire about trial or expanded access eligibility. The ongoing research aims to address resistance to RAS-targeted treatments and explore combination therapies to enhance efficacy.
